CSE1L 抗体 (N-Term)
This anti-CSE1L antibody is a 兔 多克隆 antibody detecting CSE1L in WB, IF 和 IHC (p). Suitable for 人 和 小鼠. This Primary Antibody has been cited in 8+ publications.
(8 references)Quick Overview for CSE1L 抗体 (N-Term) (ABIN1882070)
抗原
CSE1L
(Chromosome Segregation 1-Like (CSE1L))
适用
人, 小鼠
宿主
兔
克隆类型
多克隆
标记
This CSE1L antibody is un-conjugated
应用范围
Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
克隆位点
RB9332
-
-
抗原表位
- AA 55-84, N-Term
-
预测反应
- B, Zf
-
纯化方法
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
免疫原
- This Cellular Apoptosis Susceptibility antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 55-84 amino acids from the N-terminal region of human Cellular Apoptosis Susceptibility.
-
亚型
- Ig Fraction
-
-
anti-Chromosome Segregation 1-Like (CSE1L) antibody
CSE1L 适用: 人, 小鼠 WB, IHC, IF/ICC 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- IF: 1:100. WB: 1:1000. WB: 1:1000. IHC-P: 1:100. IHC-P: 1:100
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer." in: The American journal of pathology, Vol. 176, Issue 4, pp. 1619-28, (2010) (PubMed).
: "Differential distributions of CSE1L/CAS and E-cadherin in the polarized and non-polarized epithelial glands of neoplastic colorectal epithelium." in: Journal of molecular histology, Vol. 41, Issue 4-5, pp. 259-66, (2010) (PubMed).
: "Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 5, pp. 1570-7, (2009) (PubMed).
: "Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells." in: The Journal of biological chemistry, Vol. 278, Issue 47, pp. 46533-40, (2003) (PubMed).
: "CSE1L/CAS: its role in proliferation and apoptosis." in: Apoptosis : an international journal on programmed cell death, Vol. 8, Issue 1, pp. 39-44, (2003) (PubMed).
: "CAS/CSE 1 stimulates E-cadhrin-dependent cell polarity in HT-29 human colon epithelial cells." in: Biochemical and biophysical research communications, Vol. 294, Issue 4, pp. 900-5, (2002) (PubMed).
: "High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression." in: International journal of molecular medicine, Vol. 7, Issue 5, pp. 489-94, (2001) (PubMed).
: "Tissue-specific alternative splicing of the CSE1L/CAS (cellular apoptosis susceptibility) gene." in: Genomics, Vol. 58, Issue 1, pp. 41-9, (1999) (PubMed).
-
: "Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer." in: The American journal of pathology, Vol. 176, Issue 4, pp. 1619-28, (2010) (PubMed).
-
- CSE1L (Chromosome Segregation 1-Like (CSE1L))
-
别名
- Cellular Apoptosis Susceptibility
-
背景
- Proteins that carry a nuclear localization signal (NLS) are transported into the nucleus by the importin-alpha/beta heterodimer. Importin-alpha binds the NLS, while importin-beta mediates translocation through the nuclear pore complex. After translocation, RanGTP binds importin-beta and displaces importin-alpha. Importin-alpha must then be returned to the cytoplasm, leaving the NLS protein behind. CSE1L binds strongly to NLS-free importin-alpha, and this binding is released in the cytoplasm by the combined action of RANBP1 and RANGAP1. In addition, CSE1L may play a role both in apoptosis and in cell proliferation.
-
分子量
- 110417
-
NCBI登录号
- NP_001243064, NP_001307
-
UniProt
- P55060
抗原
-
You are here:
